Production (Stage)
Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 14.95% | 65.16% | |||
| Gross Profit | -14.95% | -65.16% | |||
| SG&A Expenses | 18.82% | 23.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.08% | 50.39% | |||
| Operating Income | -16.08% | -50.39% | |||
| Income Before Tax | -39.34% | 34.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -40.78% | 34.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -40.78% | 34.25% | |||
| EBIT | -16.08% | -50.39% | |||
| EBITDA | -16.24% | -50.24% | |||
| EPS Basic | -2.21% | 38.33% | |||
| Normalized Basic EPS | -1.33% | -9.71% | |||
| EPS Diluted | -2.21% | 38.33% | |||
| Normalized Diluted EPS | -1.33% | -9.71% | |||
| Average Basic Shares Outstanding | 37.62% | 6.61% | |||
| Average Diluted Shares Outstanding | 37.62% | 6.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||